Synairgen Share Price | |
---|---|
Price | 6.20 |
Bid | 6.20 |
Ask | 6.50 |
Change | 0.00 (0.00%) |
Volume | 83,867 |
Open | 6.20 |
High | 6.20 |
Low | 6.20 |
Prev. Close | 6.20 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 201.37m |
Market Capitalisation | £12.49m |
Market Size | 30,000 |
52 Week High | 10.62 |
52 Week High Date | 29-Nov-2023 |
52 Week Low | 4.20 |
52 Week Low Date | 22-Mar-2024 |
# Trades | 8 |
---|---|
Vol. Sold | 65,276 |
Sold Value | £3.94k |
Vol. Bought | 18,591 |
Bought Value | £1.19k |
PE Ratio | -0.707763 |
Earnings | -8.76 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
07-May-24 | 09:39:08 | 6.215 | 1,325 | Sell* | 6.20 | 6.50 | 82.35 | O Ordinary |
07-May-24 | 08:54:36 | 6.23 | 35,000 | Sell* | 6.20 | 6.50 | 2,181 | O Ordinary |
07-May-24 | 08:43:07 | 6.39 | 18,591 | Buy* | 6.20 | 6.50 | 1,188 | O Ordinary |
07-May-24 | 08:25:41 | 6.23 | 3,000 | Sell* | 6.20 | 6.50 | 186.90 | O Ordinary |
07-May-24 | 08:01:07 | 6.23 | 23,677 | Sell* | 6.20 | 6.50 | 1,475 | O Ordinary |
07-May-24 | 08:00:28 | 6.23 | 149 | Sell* | 6.20 | 6.50 | 9.28 | O Ordinary |
07-May-24 | 08:00:28 | 6.20 | 100 | Sell* | 6.20 | 6.50 | 6.20 | UT Uncrossing Trade |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.42 | GBX | 621 | 8,520 |
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.74 | GBX | 7,899 | 8,520 |
12-Aug-21 | 12-Aug-21 | Exercise of Option | John C Ward held the position of Finance Director at the time of this trade.John C Ward | 1.00 | GBX | 489,148 | 734,092 |
12-Aug-21 | 12-Aug-21 | Sell | Phillip David Monk held the position of Chief Scientific Officer at the time of this trade.Phillip David Monk | 140.00 | GBX | 220,878 | 423,934 |
12-Aug-21 | 12-Aug-21 | Exercise of Option | Phillip David Monk held the position of Chief Scientific Officer at the time of this trade.Phillip David Monk | 1.00 | GBX | 400,212 | 423,934 |
Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.